https://doi.org/10.1016/s0140-6736(20)32531-9
C
Cristiano Ferrario
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
235
Papers
7.8K
Citations
30
h-index
51
i10-index
Cristiano Ferrario is an academic researcher. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Cancer Genomics and Diagnostics & HER2/EGFR in Cancer Research. The author has an h-index of 30, co-authored 200 publications.
Papers by this author
worksPembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
2020 · The Lancet · 1,743 citations
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
2021 · New England Journal of Medicine · 1,447 citations
https://doi.org/10.1056/nejmoa2028485
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
2020 · The Lancet · 1,021 citations
https://doi.org/10.1016/s0140-6736(20)31953-x
Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
2020 · Scientific Reports · 92 citations
https://doi.org/10.1038/s41598-020-71236-y
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
2011 · British Journal of Cancer · 88 citations
https://doi.org/10.1038/bjc.2011.402
Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
2021 · European Journal of Cancer · 11 citations
https://doi.org/10.1016/j.ejca.2021.05.025
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat